Evotec drug extends sleep in mid-stage trial

Evotec has given a thumb's up on its Phase II data on its insomnia drug EVT 201. In the trial of 149 patients over the age of 65 researchers found that the lower dose extended sleep time by nine percent while the higher dose led to a 17 percent increase in sleep time.

- see this release on the trial

Related Articles:
Insomnia market attracts drug developers. Report
PerkinElmer acquires Evotec Tech in cash buyout. Report
Evotec adds drugs in Renovis buyout. Report
Evotec shutters Alzheimer's development program. Report

Read more on: Evotech | Insomnia

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.